Thursday, July 11, 2013

Accord Healthcare - A subsidiary of Intas Pharma gets EMA approval for Glivec generics

Accord Healthcare has received EU approval for selling Glivec generics (imatinib) in the Europe. Although the patent for Glivec expires in 2016 in the major European companies, Accord should be able to market generic copies in the smaller eastern european nations. Other generic comapnies which also have received EMA approval include Teva and Actavis. Generics have already been launched in Turkey. In Canada and Russia, the compound patent has already expired (April 2013).

Enter your email address:


Delivered by FeedBurner